Efficacy, Safety, And Tolerability Of A Wearable Electrotrichogenic Device In Men With Androgenetic Alopecia: A Randomized, Double-Blind, Sham-Controlled Trial

A recent randomized, double-blind, sham-controlled trial assessed the efficacy, safety, and tolerability of a wearable electrotrichogenic (ETG) device in men with androgenetic alopecia (AGA) over 6 months. The study involved 81 participants, with significant improvements in total hair density and hair thickness observed in the active ETG group compared to the sham group. Specifically, the active group experienced a 19.3% increase in total hair density and an 8.8% increase in hair thickness, with no adverse effects reported. The device was well-tolerated and easy to use, indicating its potential as a non-invasive, at-home treatment for AGA. However, the study was limited to men and had a follow-up period of only 6 months, suggesting the need for further research, including studies in women and longer-term evaluations.